Categories AlphaGraphs, Earnings, Health Care
AbbVie Q2 2024 adj. profit drops despite higher revenues; results beat
Specialty biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) Thursday announced second-quarter 2024 financial results, reporting a decline in adjusted earnings and an increase in revenues. The numbers exceeded estimates.
The company reported worldwide net revenues of $14.46 billion for the June quarter, up 4.3% from the corresponding period of 2023 and above the market’s projection. All operating segments, except the Eye Care division, registered growth.
Net income, adjusted for special items, declined to $2.65 per share in Q2 from $2.91 per share in the year-ago quarter, but topped expectations. On a reported basis, second-quarter profit was $1.37 billion or $0.77 per share, compared to $2.02 billion or $1.14 per share last year.
Prior Performance
Most Popular
Earnings Preview: Accenture (ACN) likely had a strong start to fiscal 2025
For Accenture plc. (NYSE: ACN), 2024 was a fruitful year marked by positive financial performance. The professional service firm effectively navigated a challenging market environment leveraging its agile business model
Signet Jewelers (SIG): Fashion remains a strong point for the jewelery retailer
Shares of Signet Jewelers Limited (NYSE: SIG) were down over 3% on Tuesday. The stock has dropped 12% over the past three months. The company faced challenges in the third
Pfizer (PFE) reaffirms FY24 forecast; provides FY25 guidance
Pharmaceutical company Pfizer Inc. (NYSE: PFE) Tuesday reaffirmed its financial outlook for fiscal 2024 and provided guidance for fiscal 2025. The company said it achieved the goal of $4 bln
